D-0077-2022 Class III Terminated
FDA drug recall D-0077-2022 was initiated by Ultra Seal Corporation on Oct 13, 2021 and is designated Class III. Reason for recall: Failed Stability Specifications: Out-of-Specification results observed for Aspirin related compound Salicylic Acid. The recall status is terminated (terminated Mar 28, 2022). Affected quantity: 519,600 tablets.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 3, 2021
- Initiation Date
- Oct 13, 2021
- Termination Date
- Mar 28, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 519,600 tablets
Product description
Afassco Pain Free Plus X-STRENGTH PAIN RELIEVER (Acetaminophen 250 mg/Aspirin 250 mg/Caffeine 65 mg) tablets, 2 Tablets/package, Packaged in 12,000 Packets/Case, PO# 19540, Mfg. for: Afassco Minden, NV 89423 (Shipping Label)
Reason for recall
Failed Stability Specifications: Out-of-Specification results observed for Aspirin related compound Salicylic Acid.
Distribution pattern
Nationwide in the USA.
Code information
Lot #: 9819, K-9819, exp. date 22-Sep
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0077-2022
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026